This invention relates to novel amino acid derivatives of formula (I) wherein the R groups have the following meanings: -R1 is -H or -(1-4C)alkyl； -R2 is -C(O)R15 or -S(O)2R15； -R3 is -H, -(1-4C)alkyl or -OR16； -R4 is -H, -(1-4C)alkyl or -OR16； -R6 is -H or -C(R16)NOR16； -R7 is -H, -halogen, -cyano； -(1-6C)alkyl, -(2-6C)alkenyl or -(2-6C)alkynyl, all optionally substituted with -amino, -hydroxyl or -halogen； -R8 is -H, -cyano, -halogen, -nitro； -(1-6C)alkyl, -(2-6C)alkenyl, -(2-6C)alkynyl or -O(1-6C)alkyl, all optionally substituted with -amino, -hydroxyl or -halogen； -(hetero)aryl, optionally substituted with -cyano, -halogen, -(1-4C)alkyl, -(1-4C)alkoxy, -(1-4C)alkoxy(1-4C)alkyl or -(hetero)aryl； -C(R16)NOR16； -C(O)N(R17)2； -C(O)R18, -C(O)OR19, -NHC(O)R20, or -NHS(O)2R21； -R9 is -H, -halogen, -cyano, or -(1-4C)alkyl, optionally substituted with -halogen； -R10 is -H or -(1-4C)alkyl； -R11 is -H； -R12 is -H, -cyano or -(1-4C)alkyl； -R13 is -H, -(1-4C)alkyl, -halogen or -formyl； -R14 is -H, -halogen, -cyano, -(1-4C)alkyl or -(hetero)aryl； or a pharmaceutically acceptable salt thereof. The compounds of this invention are highly specific for the glucocorticoid receptor and may be used for treating inflammatory diseases.
